{"filing":{"accession_number":"0001213900-26-080180","cik":"0001949257","ticker":"RDPTF","company_name":"Radiopharm Theranostics Ltd","form":"6-K","filing_date":"2026-07-22","report_date":null,"primary_document":"ea0298836-6k_radiopharm.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1949257/000121390026080180/ea0298836-6k_radiopharm.htm"},"events":[{"id":19315,"run_id":17377,"accession_number":"0001213900-26-080180","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Radiopharm Theranostics announced positive Phase 1 clinical trial results for RAD204, including a RECIST-confirmed durable partial response in an advanced solid tumor patient and favorable safety data, representing material progress on the company's lead therapeutic program.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18376,"accession_number":"0001213900-26-080180","item_number":"EX-99.1","item_title":"ea029883601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is an ASX announcement disclosing positive Phase 1 clinical trial results for RAD204, including a RECIST-confirmed durable partial response in an advanced solid tumor patient and favorable safety data. While clinical-stage biotech announcements are operational/strategic milestones rather than discrete financial or governance events, the achievement of confirmed efficacy and safety data in an ongoing Phase 1 trial represents material progress on the company's lead program that would affect a reasonable investor's assessment of development risk and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:01:04.781411+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":19316,"run_id":17377,"accession_number":"0001213900-26-080180","anchor_item_number":"EX-99.2","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Radiopharm Theranostics announced positive Phase 2b clinical trial results for RAD101, a diagnostic imaging radiopharmaceutical, achieving the primary endpoint of 93% concordance with MRI and 86% sensitivity, with advancement to Phase 3 pivotal trials planned for Q4 2026.","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-22","form":"6-K","submitted_at":null,"items":[{"id":18377,"accession_number":"0001213900-26-080180","item_number":"EX-99.2","item_title":"ea029883601ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an announcement of positive Phase 2b clinical trial results for RAD101, a diagnostic imaging radiopharmaceutical in development. The disclosure reports achievement of the primary endpoint (93% concordance with MRI) and preliminary secondary endpoint data (86% sensitivity), with plans to advance into Phase 3 pivotal trials in Q4 2026. While clinical-stage biotech companies routinely announce trial results, this positive Phase 2b outcome meeting primary endpoints and supporting advancement to pivotal Phase 3 trials is material to investors assessing the company's pipeline progress and probability of eventual commercialization in a ~$600m+ market. This is classified as operational_other rather than a specific financial or governance event, as it represents a material clinical/regulatory milestone in product development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:01:04.781411+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18376,"accession_number":"0001213900-26-080180","item_number":"EX-99.1","item_title":"ea029883601ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This is an ASX announcement disclosing positive Phase 1 clinical trial results for RAD204, including a RECIST-confirmed durable partial response in an advanced solid tumor patient and favorable safety data. While clinical-stage biotech announcements are operational/strategic milestones rather than discrete financial or governance events, the achievement of confirmed efficacy and safety data in an ongoing Phase 1 trial represents material progress on the company's lead program that would affect a reasonable investor's assessment of development risk and commercial potential.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:01:04.781411+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-22"},{"id":18377,"accession_number":"0001213900-26-080180","item_number":"EX-99.2","item_title":"ea029883601ex99-2.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"This is an announcement of positive Phase 2b clinical trial results for RAD101, a diagnostic imaging radiopharmaceutical in development. The disclosure reports achievement of the primary endpoint (93% concordance with MRI) and preliminary secondary endpoint data (86% sensitivity), with plans to advance into Phase 3 pivotal trials in Q4 2026. While clinical-stage biotech companies routinely announce trial results, this positive Phase 2b outcome meeting primary endpoints and supporting advancement to pivotal Phase 3 trials is material to investors assessing the company's pipeline progress and probability of eventual commercialization in a ~$600m+ market. This is classified as operational_other rather than a specific financial or governance event, as it represents a material clinical/regulatory milestone in product development.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-22T11:01:04.781411+00:00","company_name":"Radiopharm Theranostics Ltd","ticker":"RDPTF","filing_date":"2026-07-22"}]}